Literature DB >> 12623510

Modified range of alanine aminotransferase is insufficient for screening of hepatitis C virus infection in hemodialysis patients.

Irena Milotic1, Ivica Pavic, Ivica Maleta, Biserka Troselj-Vukic, Franko Milotic.   

Abstract

OBJECTIVE: A moderate increase in serum alanine aminotransferase (ALT) has been reported to be a helpful, low-cost tool for predicting viremia in anti-hepatitis C virus (HCV)-positive hemodialysis (HD) patients. This study focused on evaluating the effectiveness of a lowered normal serum ALT value as a screening method for HCV infection in HD patients.
MATERIAL AND METHODS: Serum ALT levels were compared with HCV virologic status in 125 patients on maintenance HD.
RESULTS: The prevalence of HCV antibodies was 23%. A total of 3.7% of viremic HD patients did not have a detectable antibody response. Using the conventional upper limit of normal for ALT of 37 IU, there was no significant difference in the frequency of elevated ALT levels between HCV RNA-positive and-negative patients. However, if the upper limit of normal for ALT was lowered to 27 IU, the difference was significant. Nevertheless, 60% of viremic patients still fell within the normal range.
CONCLUSION: Although inexpensive and widely available, the monitoring of serum ALT levels is not useful as a screening method for HCV infection in HD patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12623510     DOI: 10.1080/003655902762467611

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  3 in total

Review 1.  Epidemiology of hepatitis C in Croatia in the European context.

Authors:  Tatjana Vilibic-Cavlek; Jasmina Kucinar; Bernard Kaic; Maja Vilibic; Nenad Pandak; Ljubo Barbic; Vladimir Stevanovic; Jasmina Vranes
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

Review 2.  Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis: a comprehensive review.

Authors:  Luís Henrique Bezerra Cavalcanti Sette; Edmundo Pessoa de Almeida Lopes
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

Review 3.  Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.

Authors:  Chen-Hua Liu; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2022-07-25       Impact factor: 9.029

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.